Advice For Budding Inventors: Put Your Ideas Into Writing

Great ideas for a new technology or innovation excitedly scribbled on the backs of envelopes or on cocktail napkins may have lots of potential. But that promise will never be realized unless the ideas are transformed from scribbles to effective prose that can convince investors, technology licensing officials, or patent attorneys of their value. Why bother? These lean economic times may seem like the worst time to start trying to sell ideas--especially to investors. Not so, says Len Vernamont

Written byLaurel Joyce
| 10 min read

Register for free to listen to this article
Listen with Speechify
0:00
10:00
Share

Why bother? These lean economic times may seem like the worst time to start trying to sell ideas--especially to investors. Not so, says Len Vernamonti of the Institute for Technology Development in Jackson, Miss. "Usually when times are the worst you can find the best opportunities," says Vernamonti. "[Investors] are looking for opportunities and they're willing to take more risks now because the safe stuff is paying so poorly. If you're inventive and have ideas, now's the time to pounce."

And, of course, the technology licensing folks at universities and companies are always pleased to help their faculty or employees develop an idea that might yield a profitable patent and product for both the institution and the inventor.

But before seeking evaluation of an idea, patent advice, or funding, inventive scientists must follow a few important guidelines as soon as the idea is born, says Scott Taper, licensing associate for ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies